Medicines

Find Medicines

Search 21,000+ medicines by brand, generic, indication, or drug class

Medicine Indications Drug Classes
    Showing all medicines (21591 total)

    Labpan

    Pantoprazole Sodium Sesquihydrate
    Tablet (Enteric Coated) 40 mg Allopathic Proton Pump Inhibitor

    Indications

    Zollinger-Ellison syndrome

    Indication detailsView
    Pantoprazole is indicated where suppression of acid secretion has therapeutic benefit; i.e 
    • Peptic ulcer diseases
    • Gastroesophageal reflux diseases
    • Ulcer induced by non-steroidal anti-inflammatory drugs (NSAIDs)
    • Eradication of Helicobacter pylori (in combination with antibiotics)
    • Zollinger-Ellison Syndrome
    Therapeutic classView
    Proton Pump Inhibitor
    PharmacologyView
    Pantoprazole is a proton pump inhibitor that suppresses the final step in gastric acid production by covalently binding to the H+/K+ATPase enzyme system at the surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus that persists longer than 24 hours.
    DosageView
    Oral:
    • Benign gastric ulcer: 40 mg daily in the morning for 4 weeks, continued for further 4 weeks, if not fully healed.
    • Gastro-esophageal reflux disease: 20-40 mg daily in the morning for 4 weeks, continued for further 4 weeks, if not fully healed; maintenance dose is 20 mg daily, which may be increased to 40 mg daily.
    • Duodenal ulcer: 40 mg daily in the morning for 2 weeks, continued for further 2 weeks if not fully healed.
    • Duodenal ulcer associated with Helicobacter pylori: Pantoprazole is recommended at a dose of 40 mg twice daily in association with antimicrobial agents as detailed below: Amoxycillin 1 g and Clarithromycin 500 mg both twice daily for one week, or Clarithromycin 250 mg and Metronidazole 400 mg both twice daily for one week.
    • Prophylaxis of NSAID-associated gastric or duodenal ulcer: 20 mg daily for those require long-term NSAID treatment.
    • Zollinger-Ellison Syndrome: Initially 80 mg once daily adjusted according to response (elderly max. 40 mg daily); daily doses above 80 mg given in 2 divided doses.

    IV Injection:
    • Duodenal ulcer and gastric ulcer: 40 mg once daily for 7-10 days
    • Gastroesophageal reflux disease associated with a history of erosive esophagitis: 40 mg once daily for 7-10 days
    • Prevention of rebleeding in peptic ulcer: IV 80 mg, followed by 8 mg/hour infusion for 72 hours
    • Prophylaxis of acid aspiration: 80 mg IV every 12 h for 24 h, followed by 40mg every 12 hour
    • Long-term management of Zollinger-Ellison Syndrome and other pathological hypersecretory conditions: 80 mg IV every 12 hours, may increase to 80 mg every 8 hours if needed, may titrate to higher doses depending on acid output.
    Side effectsView
    Pantoprazole is well tolerated in both short-term and long-term treatment. Headache and diarrhea are the common side effects and rarely included side effects are abdominal pain, flatulence, rash, insomnia and hyperglycemia.
    ContraindicationsView
    Pantoprazole is contraindicated in patients with known hypersensitivity to any of the components of the formulation.
    PrecautionsView
    Patients should be cautioned that Pantoprazole tablet should not be split, chewed or crushed. Long-term therapy of Pantoprazole may lead to malabsorption of cyanocobalamin (Vitamin B12) or may increase the risk of osteoporosis related disorders.
    InteractionsView
    No significant drug interactions have been observed in clinical studies.
    Pregnancy & lactationView
    US FDA Pregnancy Category of Pantoprazole is B. There are, however, no adequate and well-controlled studies in pregnant woman. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Pantoprazole has been shown to be excreted in human milk. So, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the benefit of the drug to the mother.
    Overdose effectsView
    There are no known symptoms of overdosage in humans. Since Pantoprazole is highly protein bound, it is not readily dialyzable. Apart from symptomatic and supportive management, no specific therapy is recommended.
    ReconstitutionView
    Direction for use of IV injection: Pantoprazole lyophilized powder and 0.9% Sodium Chloride Injection is for intravenous administration only and must not be given by any other route. Pantoprazole IV injection should be given as a slow intravenous injection. The solution for IV injection is obtained by adding 10 ml 0.9% Sodium Chloride Injection to the vial containing powder. After reconstitution the injection should be given slowly over a period of at least 2 to 5 minutes. Use only freshly prepared solution. The reconstituted solution may be stored at room temperature (up to 30° C) for a maximum 4 hours.

    Direction for use of IV infusion: Pantoprazole IV infusion should be given as an intravenous infusion over a period of approximately 15 minutes. Pantoprazole IV infusion should be reconstituted with 10 ml of 0.9% Sodium Chloride Injection and further diluted (admixed) with 0.9% Sodium Chloride Injection or 5% Dextrose or Lactated Ringer's Injection to a final volume of 100 ml. The reconstituted solution may be stored at room temperature (up to 30° C) for a maximum 4 hours prior to further dilution. The admixed solution may be stored at room temperature (up to 30° C) and must be used within 24 hours from the time of initial reconstitution.
    StorageView
    Keep in a dry place, away from light and heat. Keep out of the reach of children.

    Labpan

    Pantoprazole Sodium Sesquihydrate
    Tablet (Enteric Coated) 20 mg Allopathic Proton Pump Inhibitor

    Indications

    Zollinger-Ellison syndrome

    Indication detailsView
    Pantoprazole is indicated where suppression of acid secretion has therapeutic benefit; i.e 
    • Peptic ulcer diseases
    • Gastroesophageal reflux diseases
    • Ulcer induced by non-steroidal anti-inflammatory drugs (NSAIDs)
    • Eradication of Helicobacter pylori (in combination with antibiotics)
    • Zollinger-Ellison Syndrome
    Therapeutic classView
    Proton Pump Inhibitor
    PharmacologyView
    Pantoprazole is a proton pump inhibitor that suppresses the final step in gastric acid production by covalently binding to the H+/K+ATPase enzyme system at the surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus that persists longer than 24 hours.
    DosageView
    Oral:
    • Benign gastric ulcer: 40 mg daily in the morning for 4 weeks, continued for further 4 weeks, if not fully healed.
    • Gastro-esophageal reflux disease: 20-40 mg daily in the morning for 4 weeks, continued for further 4 weeks, if not fully healed; maintenance dose is 20 mg daily, which may be increased to 40 mg daily.
    • Duodenal ulcer: 40 mg daily in the morning for 2 weeks, continued for further 2 weeks if not fully healed.
    • Duodenal ulcer associated with Helicobacter pylori: Pantoprazole is recommended at a dose of 40 mg twice daily in association with antimicrobial agents as detailed below: Amoxycillin 1 g and Clarithromycin 500 mg both twice daily for one week, or Clarithromycin 250 mg and Metronidazole 400 mg both twice daily for one week.
    • Prophylaxis of NSAID-associated gastric or duodenal ulcer: 20 mg daily for those require long-term NSAID treatment.
    • Zollinger-Ellison Syndrome: Initially 80 mg once daily adjusted according to response (elderly max. 40 mg daily); daily doses above 80 mg given in 2 divided doses.

    IV Injection:
    • Duodenal ulcer and gastric ulcer: 40 mg once daily for 7-10 days
    • Gastroesophageal reflux disease associated with a history of erosive esophagitis: 40 mg once daily for 7-10 days
    • Prevention of rebleeding in peptic ulcer: IV 80 mg, followed by 8 mg/hour infusion for 72 hours
    • Prophylaxis of acid aspiration: 80 mg IV every 12 h for 24 h, followed by 40mg every 12 hour
    • Long-term management of Zollinger-Ellison Syndrome and other pathological hypersecretory conditions: 80 mg IV every 12 hours, may increase to 80 mg every 8 hours if needed, may titrate to higher doses depending on acid output.
    Side effectsView
    Pantoprazole is well tolerated in both short-term and long-term treatment. Headache and diarrhea are the common side effects and rarely included side effects are abdominal pain, flatulence, rash, insomnia and hyperglycemia.
    ContraindicationsView
    Pantoprazole is contraindicated in patients with known hypersensitivity to any of the components of the formulation.
    PrecautionsView
    Patients should be cautioned that Pantoprazole tablet should not be split, chewed or crushed. Long-term therapy of Pantoprazole may lead to malabsorption of cyanocobalamin (Vitamin B12) or may increase the risk of osteoporosis related disorders.
    InteractionsView
    No significant drug interactions have been observed in clinical studies.
    Pregnancy & lactationView
    US FDA Pregnancy Category of Pantoprazole is B. There are, however, no adequate and well-controlled studies in pregnant woman. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Pantoprazole has been shown to be excreted in human milk. So, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the benefit of the drug to the mother.
    Overdose effectsView
    There are no known symptoms of overdosage in humans. Since Pantoprazole is highly protein bound, it is not readily dialyzable. Apart from symptomatic and supportive management, no specific therapy is recommended.
    ReconstitutionView
    Direction for use of IV injection: Pantoprazole lyophilized powder and 0.9% Sodium Chloride Injection is for intravenous administration only and must not be given by any other route. Pantoprazole IV injection should be given as a slow intravenous injection. The solution for IV injection is obtained by adding 10 ml 0.9% Sodium Chloride Injection to the vial containing powder. After reconstitution the injection should be given slowly over a period of at least 2 to 5 minutes. Use only freshly prepared solution. The reconstituted solution may be stored at room temperature (up to 30° C) for a maximum 4 hours.

    Direction for use of IV infusion: Pantoprazole IV infusion should be given as an intravenous infusion over a period of approximately 15 minutes. Pantoprazole IV infusion should be reconstituted with 10 ml of 0.9% Sodium Chloride Injection and further diluted (admixed) with 0.9% Sodium Chloride Injection or 5% Dextrose or Lactated Ringer's Injection to a final volume of 100 ml. The reconstituted solution may be stored at room temperature (up to 30° C) for a maximum 4 hours prior to further dilution. The admixed solution may be stored at room temperature (up to 30° C) and must be used within 24 hours from the time of initial reconstitution.
    StorageView
    Keep in a dry place, away from light and heat. Keep out of the reach of children.

    Lacicard

    Lacidipine
    Tablet 4 mg Allopathic Calcium-channel blockers

    Indications

    Stroke

    Indication detailsView
    Lacidipine is indicated for the treatment of hypertension either alone or in combination with other antihypertensive agents, including ß-blockers, diuretics, ACE-inhibitors etc.
    Therapeutic classView
    Calcium-channel blockers
    PharmacologyView
    Lacidipine inhibits the influx of calcium into smooth muscle cells by the competitive inhibition of voltage-dependent calcium 'L' channels. This action results in the inhibition of the effects triggered by the influx of calcium into the cells, such as the activation of the contractile proteins in smooth muscle.
    DosageView
    The recommended initial dose of Lacidipine is 2 mg once daily. The dose may be increased to 4 mg and then, if necessary, to 6 mg after 3 to 4 weeks. Lacidipine should be taken preferably in the morning.
    Side effectsView
    Lacidipine is generally well tolerated. Some individuals may experience minor side effects like flushing, palpitation, edema, headache, dizziness, rarely gastro-intestinal disturbances, gum hyperplasia, mood disturbances, asthenia, polyuria, muscle cramps, skin rash etc.
    ContraindicationsView
    Hypersensitivity to any ingredient of this product, cardiogenic shock, unstable angina, aortic stenosis, avoid within 1 month of myocardial infarction, impaired left ventricular function.
    PrecautionsView
    Cardiac conduction abnormalities, poor cardiac reserves, hepatic impairment, withdraw if ischemic pain occurs shortly after initiating treatment or if cardiogenic shock develops, avoid grape fruit juice.
    InteractionsView
    The plasma concentration of Lacidipine may be increased by simultaneous administration of cimetidine. No specific pharmacodynamic interaction problems have been identified in studies with common antihypertensive agents or with digoxin, tolbutamide or warfarin.
    Pregnancy & lactationView
    Pregnancy: There are no data on the safety of Lacidipine in human pregnancy. Lacidipine provides no evidence of a teratogenic effect in animal study.

    Lactation: Milk transfer studies in animals have shown that Lacidipine (or its metabolites) are likely to be excreted into breast milk. There is, however, no clinical experience of Lacidipine in pregnancy and lactation. Accordingly, Lacidipine should not be used during pregnancy or lactation.
    Pediatric usageView
    Use in Neonates: There are no data on safety or efficacy of Lacidipine in neonates.
    Use in children: Treatment with Lacidipine have not been evaluated in Children.
    Hepatic Impairment: Severe: Reduce dose.
    Overdose effectsView
    Symptoms: Prolonged peripheral vasodilation associated with hypotension and tachycardia, bradycardia or prolonged AV conduction.

    Management: Symptomatic and supportive treatment.
    StorageView
    Store in a cool and dry place, protect from light and moisture. Keep out of the reach of children.

    Lacicard

    Lacidipine
    Tablet 2 mg Allopathic Calcium-channel blockers

    Indications

    Stroke

    Indication detailsView
    Lacidipine is indicated for the treatment of hypertension either alone or in combination with other antihypertensive agents, including ß-blockers, diuretics, ACE-inhibitors etc.
    Therapeutic classView
    Calcium-channel blockers
    PharmacologyView
    Lacidipine inhibits the influx of calcium into smooth muscle cells by the competitive inhibition of voltage-dependent calcium 'L' channels. This action results in the inhibition of the effects triggered by the influx of calcium into the cells, such as the activation of the contractile proteins in smooth muscle.
    DosageView
    The recommended initial dose of Lacidipine is 2 mg once daily. The dose may be increased to 4 mg and then, if necessary, to 6 mg after 3 to 4 weeks. Lacidipine should be taken preferably in the morning.
    Side effectsView
    Lacidipine is generally well tolerated. Some individuals may experience minor side effects like flushing, palpitation, edema, headache, dizziness, rarely gastro-intestinal disturbances, gum hyperplasia, mood disturbances, asthenia, polyuria, muscle cramps, skin rash etc.
    ContraindicationsView
    Hypersensitivity to any ingredient of this product, cardiogenic shock, unstable angina, aortic stenosis, avoid within 1 month of myocardial infarction, impaired left ventricular function.
    PrecautionsView
    Cardiac conduction abnormalities, poor cardiac reserves, hepatic impairment, withdraw if ischemic pain occurs shortly after initiating treatment or if cardiogenic shock develops, avoid grape fruit juice.
    InteractionsView
    The plasma concentration of Lacidipine may be increased by simultaneous administration of cimetidine. No specific pharmacodynamic interaction problems have been identified in studies with common antihypertensive agents or with digoxin, tolbutamide or warfarin.
    Pregnancy & lactationView
    Pregnancy: There are no data on the safety of Lacidipine in human pregnancy. Lacidipine provides no evidence of a teratogenic effect in animal study.

    Lactation: Milk transfer studies in animals have shown that Lacidipine (or its metabolites) are likely to be excreted into breast milk. There is, however, no clinical experience of Lacidipine in pregnancy and lactation. Accordingly, Lacidipine should not be used during pregnancy or lactation.
    Pediatric usageView
    Use in Neonates: There are no data on safety or efficacy of Lacidipine in neonates.
    Use in children: Treatment with Lacidipine have not been evaluated in Children.
    Hepatic Impairment: Severe: Reduce dose.
    Overdose effectsView
    Symptoms: Prolonged peripheral vasodilation associated with hypotension and tachycardia, bradycardia or prolonged AV conduction.

    Management: Symptomatic and supportive treatment.
    StorageView
    Store in a cool and dry place, protect from light and moisture. Keep out of the reach of children.

    Lacitab

    Lacidipine
    Tablet 2 mg Allopathic Calcium-channel blockers

    Indications

    Stroke

    Indication detailsView
    Lacidipine is indicated for the treatment of hypertension either alone or in combination with other antihypertensive agents, including ß-blockers, diuretics, ACE-inhibitors etc.
    Therapeutic classView
    Calcium-channel blockers
    PharmacologyView
    Lacidipine inhibits the influx of calcium into smooth muscle cells by the competitive inhibition of voltage-dependent calcium 'L' channels. This action results in the inhibition of the effects triggered by the influx of calcium into the cells, such as the activation of the contractile proteins in smooth muscle.
    DosageView
    The recommended initial dose of Lacidipine is 2 mg once daily. The dose may be increased to 4 mg and then, if necessary, to 6 mg after 3 to 4 weeks. Lacidipine should be taken preferably in the morning.
    Side effectsView
    Lacidipine is generally well tolerated. Some individuals may experience minor side effects like flushing, palpitation, edema, headache, dizziness, rarely gastro-intestinal disturbances, gum hyperplasia, mood disturbances, asthenia, polyuria, muscle cramps, skin rash etc.
    ContraindicationsView
    Hypersensitivity to any ingredient of this product, cardiogenic shock, unstable angina, aortic stenosis, avoid within 1 month of myocardial infarction, impaired left ventricular function.
    PrecautionsView
    Cardiac conduction abnormalities, poor cardiac reserves, hepatic impairment, withdraw if ischemic pain occurs shortly after initiating treatment or if cardiogenic shock develops, avoid grape fruit juice.
    InteractionsView
    The plasma concentration of Lacidipine may be increased by simultaneous administration of cimetidine. No specific pharmacodynamic interaction problems have been identified in studies with common antihypertensive agents or with digoxin, tolbutamide or warfarin.
    Pregnancy & lactationView
    Pregnancy: There are no data on the safety of Lacidipine in human pregnancy. Lacidipine provides no evidence of a teratogenic effect in animal study.

    Lactation: Milk transfer studies in animals have shown that Lacidipine (or its metabolites) are likely to be excreted into breast milk. There is, however, no clinical experience of Lacidipine in pregnancy and lactation. Accordingly, Lacidipine should not be used during pregnancy or lactation.
    Pediatric usageView
    Use in Neonates: There are no data on safety or efficacy of Lacidipine in neonates.
    Use in children: Treatment with Lacidipine have not been evaluated in Children.
    Hepatic Impairment: Severe: Reduce dose.
    Overdose effectsView
    Symptoms: Prolonged peripheral vasodilation associated with hypotension and tachycardia, bradycardia or prolonged AV conduction.

    Management: Symptomatic and supportive treatment.
    StorageView
    Store in a cool and dry place, protect from light and moisture. Keep out of the reach of children.

    Lacitab

    Lacidipine
    Tablet 4 mg Allopathic Calcium-channel blockers

    Indications

    Stroke

    Indication detailsView
    Lacidipine is indicated for the treatment of hypertension either alone or in combination with other antihypertensive agents, including ß-blockers, diuretics, ACE-inhibitors etc.
    Therapeutic classView
    Calcium-channel blockers
    PharmacologyView
    Lacidipine inhibits the influx of calcium into smooth muscle cells by the competitive inhibition of voltage-dependent calcium 'L' channels. This action results in the inhibition of the effects triggered by the influx of calcium into the cells, such as the activation of the contractile proteins in smooth muscle.
    DosageView
    The recommended initial dose of Lacidipine is 2 mg once daily. The dose may be increased to 4 mg and then, if necessary, to 6 mg after 3 to 4 weeks. Lacidipine should be taken preferably in the morning.
    Side effectsView
    Lacidipine is generally well tolerated. Some individuals may experience minor side effects like flushing, palpitation, edema, headache, dizziness, rarely gastro-intestinal disturbances, gum hyperplasia, mood disturbances, asthenia, polyuria, muscle cramps, skin rash etc.
    ContraindicationsView
    Hypersensitivity to any ingredient of this product, cardiogenic shock, unstable angina, aortic stenosis, avoid within 1 month of myocardial infarction, impaired left ventricular function.
    PrecautionsView
    Cardiac conduction abnormalities, poor cardiac reserves, hepatic impairment, withdraw if ischemic pain occurs shortly after initiating treatment or if cardiogenic shock develops, avoid grape fruit juice.
    InteractionsView
    The plasma concentration of Lacidipine may be increased by simultaneous administration of cimetidine. No specific pharmacodynamic interaction problems have been identified in studies with common antihypertensive agents or with digoxin, tolbutamide or warfarin.
    Pregnancy & lactationView
    Pregnancy: There are no data on the safety of Lacidipine in human pregnancy. Lacidipine provides no evidence of a teratogenic effect in animal study.

    Lactation: Milk transfer studies in animals have shown that Lacidipine (or its metabolites) are likely to be excreted into breast milk. There is, however, no clinical experience of Lacidipine in pregnancy and lactation. Accordingly, Lacidipine should not be used during pregnancy or lactation.
    Pediatric usageView
    Use in Neonates: There are no data on safety or efficacy of Lacidipine in neonates.
    Use in children: Treatment with Lacidipine have not been evaluated in Children.
    Hepatic Impairment: Severe: Reduce dose.
    Overdose effectsView
    Symptoms: Prolonged peripheral vasodilation associated with hypotension and tachycardia, bradycardia or prolonged AV conduction.

    Management: Symptomatic and supportive treatment.
    StorageView
    Store in a cool and dry place, protect from light and moisture. Keep out of the reach of children.

    Lacitone

    Furosemide + Spironolactone
    Tablet 20 mg+50 mg Allopathic Potassium-sparing diuretics

    Indications

    Hypertension

    Indication detailsView
    Frusemide & Spironolactone combination is indicated in-
    • Essential hypertension
    • Chronic congestive heart failure
    • Hepatic cirrhosis, with collection of fluid in the abdominal cavity (ascites)
    • Swelling due to excess fluid retention (edema)
    • Hyperaldosteronism
    • Resistant edema associated with secondary hyperaldosteronism
    Therapeutic classView
    Potassium-sparing diuretics, Potassium-sparing diuretics & Aldosterone antagonists
    PharmacologyView
    Spironolactone (potassium sparing diuretic) and Furosemide (loop diuretic) have different but complementary mechanisms and sites of action. Therefore, when given together they produce additive or synergistic diuretic. The Furosemide component inhibits the Na+/K+/2Cl- co-transporter in the ascending Loop of Henle and blocks the reabsorption of sodium, potassium and chloride ions; thereby increasing the quantity of sodium and the volume of water excreted in the urine. This characteristically induces potassium loss. The spironolactone component inhibits the reabsorption of sodium in exchange for potassium at the distal tubule by antagonising the action of aldosterone so that sodium excretion is greatly favoured and the excess loss of potassium, induced by the Furosemide, is reduced
    DosageView
    Furosemide 20 and spironolactone 50 mg: 1 to 4 tablets daily (20 to 80 mg of Furosemide and 50 to 200 mg of spironolactone) according to the patient’s response.

    Furosemide 40 and spironolactone 50 mg: For previously stabilized patients requiring a higher dosage of spironolactone and Furosemide, This tablet can be used at a dose of one to two tablets daily (Furosemide 40 to 80 mg and spironolactone 50 to 100 mg).

    Use in children: Spironolactone and Furosemide is not suitable for use in children. Spironolactone and Furosemide may both be excreted more slowly in the elderly.
    Side effectsView
    Spironolactone may give rise to headache and drowsiness and gastrointestinal distress, including cramp and diarrhoea. Ataxia, mental confusion, and skin rashes have been reported as side effect. Gynaecomastia is not uncommon and in rare cases breast enlargement may persist. Other endocrine disorders including hirsutism, deepening of the voice, menstrual irregularities and impotence. Transient increase in blood-urea-nitrogen concentrations may occur and mild acidosis has been reported. Spironolactone may cause hyponatremia and hyperkalemia. Excessive diuresis may result in dehydration and reduction in blood volume with circulatory collapse with the possibility of vascular thrombosis and embolism particularly in elderly patients. Serious depletion of potassium and magnesium may lead to cardiac arrhythmias.
    ContraindicationsView
    Contraindicated in patients with anuria, acute renal insufficiency, rapidly deteriorating or severe impairment of renal function (creatinine clearance <30 ml/min), hyperkalaemia, Addison's disease and in patients who are hypersensitive to Spironolactone, Furosemide or sulphonamides.
    PrecautionsView
    Caution should be taken in patients liable to electrolyte deficiency. This preparation should also be used with caution in diabetes, enlarged prostate, hypotension and in hypovolemia.
    InteractionsView
    When taken together with ACE inhibitors or potassium salts there is an increased risk of hyperkalemia. Spironolactone increases the levels of cardiac glycosides such as digoxin in the blood and this may result in digitalis toxicity. Corticosteroids may cause hypokalemia if they are used with Spironolactone. The blood pressure lowering and diuretic effects of Furosemide may be reduced or abolished when used together with indomethacin and possibly other non-steroidal anti-inflammatory drugs (NSAIDs). Furosemide may increase the ototoxicity of aminoglycoside antibiotics. Simultaneous administration of sucralfate and Furosemide may reduce the natriuretic and anti-hypertensive effect of Furosemide.
    Pregnancy & lactationView
    Pregnancy: Spironolactone and its metabolites may cross the placental barrier. The use of spironolactone in pregnant women requires that the anticipated benefit be weighed against the possible hazards to the mother and fetus. Animal teratology studies indicate that Furosemide may cause fetal abnormalities. Therefore, Furosemide should only be used in women in child bearing age when appropriate contraceptive measures are taken or if the potential benefits justify the potential risks to the fetus.

    Lactation: Metabolites of Spironolactone have been detected in breast milk. If use of Spironolactone is considered essential, an alternative method of infant feeding should be instituted. Furosemide is excreted in breast milk and breast-feeding should be discontinued if treatment is essential.
    StorageView
    Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

    Laclose

    Lactulose
    Oral Solution 3.35 gm/5 ml Allopathic Osmotic purgatives

    Indications

    Osmotic laxative

    Indication detailsView
    Constipation (Chronic Constipation): In every case of chronic constipation, initial treatment should consist of a diet rich in fiber (vegetables, salads, fruits etc.) a generous amount of liquids and much physical exercise. Lactulose is only to be taken when these measures prove insufficient.

    Intestinal flora disturbances:
    • In damaged to intestinal flora (e.g. following long-term antibiotic treatment)
    • gall bladder diseases
    • intestinal diseases ( Colitis, Diverticulosis, Megacolon)
    Increased blood ammonia levels (hyper ammoniemia in hepatopathy, portal-systemic encephalopathy)
    Therapeutic classView
    Osmotic purgatives
    PharmacologyView
    Lactulose is a synthetic disaccharide. Lactulose is metabolized in the colon by the saccharolytic bacteria, producing low molecular weight organic acids (mainly lactic acid), which lowers the pH of the colon contents, promote the retention of water by an osmotic effect; thus increasing peristaltic activity. Lactulose is minimally absorbed; therefore, the pharmacokinetics of the absorbed material are not relevant to the principal therapeutic action.
    DosageView
    In constipation ( chronic constipation):
    • Adults: Initially 3-6 tea-spoons daily, In long-term therapy 1½-6 tea-spoons daily
    • Children up to 14 years: Initially 3 tea-spoons daily, In long-term therapy 1-2 tea-spoons daily
    • Infants and toddlers: Initially 1-2 tea-spoons daily, In long-term therapy 1 tea-spoon daily
    In damaged intestinal flora:
    • Adults: 1-2 tea-spoons daily
    • Children: 1 tea-spoon daily
    For reduction of blood ammonia level:
    • Hyper-ammoniemia in hepatopathy: a maximum of 18-30 tea-spoons daily.
    • In portal systemic encephalopathy: hourly doses of 6-9 tea-spoons of Lactulose solution may be used to induce the rapid laxation. When the laxative effect has been achieved, the dose may then be reduced.
    Side effectsView
    Occasionally flatulence, cramp and abdominal discomfort can occur at the beginning of treatment; this is rapidly eliminated by reducing the dose. Overdose can result in diarrhoea. In abuse, loss of electrolytes (primarily potassium).
    ContraindicationsView
    Hypersensitivity to either galactose and or lactose; galactose-free diet, gastro-cardial symptom complex, suspected intestinal obstruction.
    PrecautionsView
    Lactulose should be administered with care to patients who are intolerant to lactulose. The dose used in the treatment of (pre) coma hepaticum is usually much higher and may need to be taken into consideration for diabetics.
    InteractionsView
    There is no significant drug interactions with lactulose. The glycosidic effect of cardiac glycosides can be intensified by potassium deficiency in abuse.
    Pregnancy & lactationView
    US FDA Pregnancy Category of Lactulose is B. Studies show that Lactulose has no adverse effects. Decisions regarding use during pregnancy and lactation must be made by registered physician.
    Overdose effectsView
    There have been no reports of accidental overdosage. In the event of acute overdosage it is expected that diarrhoea and abdominal cramps would be the major symptoms.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.

    Lacor

    Ketorolac Tromethamine
    Tablet 10 mg Allopathic Drugs used for Rheumatoid Arthritis

    Indications

    Soft tissue inflammation

    Indication detailsView
    Ketorolac Tromethamine is indicated for the short-term management of moderate to severe acute post-operative pain.
    Therapeutic classView
    Drugs used for Rheumatoid Arthritis, Non-Opioid Analgesics
    PharmacologyView
    Ketorolac Tromethamine is a potent analgesic of the non-steroidal anti-inflammatory drugs (NSAIDs). It acts by inhibiting the cyclooxygenase enzyme system and hence inhibits the prostaglandin synthesis. It demonstrates a minimal anti-inflammatory effect at its analgesic dose.
    DosageView

    Tablet-

    Recommended dose is 10 mg every 4-6 hours. It should be used short-term only (up to 7 days) and are not recommended for chronic use. Doses exceeding 40 mg/day is not recommended.

    Injection-

    Ketorolac injection may be used as a single or multiple doses, on a regular or when necessary schedule for the management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. When administering Ketorolac injection, the IV bolus must be given over no less than 15 seconds. The IM administration should be given slowly and deeply into the muscle. The analgesic effect begins within 30 minutes with maximum effect in 1 to 2 hours after dosing IV or IM. Duration of analgesic effect is usually 4 to 6 hours.

    Single-Dose Treatment-
    IM Dosing (Adult):
    • Patients <65 years of age: One dose of 60 mg.
    • Patients >65 years of age, renally impaired and/or less than 50 kg of body weight: One dose of 30 mg.
    IV Dosing (Adult):
    • Patients <65 years of age: One dose of 30 mg.
    • Patients >65 years of age, renally impaired and/or less than 50 kg of body weight: One dose of 15 mg.
    IV or IM Dosing (2 to 16 years of age):
    • IM Dosing: One dose of 1 mg/kg up to a maximum of 30 mg.
    • IV Dosing: One dose of 0.5 mg/kg up to a maximum of 15 mg.
    Multiple-Dose Treatment (IV or IM)-
    • Patients <65 years of age: The recommended dose is 30 mg Ketorolac injection every 6 hours. The maximum daily dose should not exceed 120 mg. Patients >65 years of age, renally impaired patients and patients less than 50 kg: The recommended dose is 15 mg Ketorolac injection every 6 hours. The maximum daily dose for these populations should not exceed 60 mg. For breakthrough pain, do not increase the dose or the frequency of Ketorolac Tromethamine.
    • Conversion from Parenteral to Oral Therapy: Ketorolac tablets may be used either as monotherapy or as follow-on therapy to parenteral Ketorolac. When Ketorolac tablets are used as a follow-on therapy to parenteral Ketorolac, the total combined daily dose of ketorolac (oral + parenteral) should not exceed 120 mg in younger adult patients or 60 mg in elderly patients on the day the change of formulation is made. On subsequent days, oral dosing should not exceed the recommended daily maximum of 40 mg. Ketorolac IM should be replaced by Ketorolac tablet as soon as feasible. The total duration of combined parenteral and oral treatment should not exceed 5 days.
    Side effectsView
    Commonly occurring side effects are nausea, vomiting, gastro-intestinal bleeding, melana, peptic ulcer, pancreatitis, anxiety, drowsiness, headache, excessive thirst, fatigue, bradycardia, hypertension, palpitation, chest pain, infertility in female and pulmonary edema.
    ContraindicationsView
    Ketorolac is contraindicated in patients having hypersensitivity to this drug or other NSAIDs. It should not be used in children under 16 years of age. lt is also contraindicated as prophylactic analgesic before surgery.
    PrecautionsView
    Caution should be exercised in patients over the age of 65 years. Caution should also be taken in patients with active or suspected peptic ulcer or gastrointestinal bleeding or asthma and liver dysfunction.
    InteractionsView
    Other NSAIDs or aspirin: Increase the side effects of ketorolac Tromethamine.
    Anti-coagulants: Enhance anti-coagulant effect.
    Beta Blocker: Reduce the anti-hypertensive effect .
    ACE Inhibitors: Increase the risk of renal impairment.
    Methotrexate: Enhance the toxicity of methotrexate.
    Pregnancy & lactationView
    US FDA Pregnancy category of Ketorolac Tromethamine is C. So, Ketorolac Tromethamine should be avoided in pregnancy and lactation unless the potential benefits to the other outweigh the possible risks to the fetus.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.

    Lacos

    Lactulose
    Oral Solution 3.35 gm/5 ml Allopathic Osmotic purgatives

    Indications

    Osmotic laxative

    Indication detailsView
    Constipation (Chronic Constipation): In every case of chronic constipation, initial treatment should consist of a diet rich in fiber (vegetables, salads, fruits etc.) a generous amount of liquids and much physical exercise. Lactulose is only to be taken when these measures prove insufficient.

    Intestinal flora disturbances:
    • In damaged to intestinal flora (e.g. following long-term antibiotic treatment)
    • gall bladder diseases
    • intestinal diseases ( Colitis, Diverticulosis, Megacolon)
    Increased blood ammonia levels (hyper ammoniemia in hepatopathy, portal-systemic encephalopathy)
    Therapeutic classView
    Osmotic purgatives
    PharmacologyView
    Lactulose is a synthetic disaccharide. Lactulose is metabolized in the colon by the saccharolytic bacteria, producing low molecular weight organic acids (mainly lactic acid), which lowers the pH of the colon contents, promote the retention of water by an osmotic effect; thus increasing peristaltic activity. Lactulose is minimally absorbed; therefore, the pharmacokinetics of the absorbed material are not relevant to the principal therapeutic action.
    DosageView
    In constipation ( chronic constipation):
    • Adults: Initially 3-6 tea-spoons daily, In long-term therapy 1½-6 tea-spoons daily
    • Children up to 14 years: Initially 3 tea-spoons daily, In long-term therapy 1-2 tea-spoons daily
    • Infants and toddlers: Initially 1-2 tea-spoons daily, In long-term therapy 1 tea-spoon daily
    In damaged intestinal flora:
    • Adults: 1-2 tea-spoons daily
    • Children: 1 tea-spoon daily
    For reduction of blood ammonia level:
    • Hyper-ammoniemia in hepatopathy: a maximum of 18-30 tea-spoons daily.
    • In portal systemic encephalopathy: hourly doses of 6-9 tea-spoons of Lactulose solution may be used to induce the rapid laxation. When the laxative effect has been achieved, the dose may then be reduced.
    Side effectsView
    Occasionally flatulence, cramp and abdominal discomfort can occur at the beginning of treatment; this is rapidly eliminated by reducing the dose. Overdose can result in diarrhoea. In abuse, loss of electrolytes (primarily potassium).
    ContraindicationsView
    Hypersensitivity to either galactose and or lactose; galactose-free diet, gastro-cardial symptom complex, suspected intestinal obstruction.
    PrecautionsView
    Lactulose should be administered with care to patients who are intolerant to lactulose. The dose used in the treatment of (pre) coma hepaticum is usually much higher and may need to be taken into consideration for diabetics.
    InteractionsView
    There is no significant drug interactions with lactulose. The glycosidic effect of cardiac glycosides can be intensified by potassium deficiency in abuse.
    Pregnancy & lactationView
    US FDA Pregnancy Category of Lactulose is B. Studies show that Lactulose has no adverse effects. Decisions regarding use during pregnancy and lactation must be made by registered physician.
    Overdose effectsView
    There have been no reports of accidental overdosage. In the event of acute overdosage it is expected that diarrhoea and abdominal cramps would be the major symptoms.
    StorageView
    Keep in a dry place away from light and heat. Keep out of the reach of children.

    Lacrigel

    Carboxymethylcellulose Sodium
    Ophthalmic Solution 1% Allopathic
    Indication detailsView
    It is used as a lubricant to relieve irritation and discomfort due to dryness of the eye or due to exposure to wind or sun.
    PharmacologyView
    Carboxymethylcellulose binds to the surface of corneal epithelial cells via its glucopyranose subunits binding to glucose receptors GLUT-1. The residence time of carboxymethylcellulose bound to corneal cells is approximately 2 hours as indicated by a short-term binding assay. Binding of carboxymethylcellulose to the matrix proteins stimulated corneal epithelial cell attachment, migration, and re-epithelialization of corneal wounds.

    This eye drop contains Carboxymethylcellulose Sodium similar to normal tears which acts as an ocular lubricant. It provides a lubricating and hydrating protective shield on the ocular surface.
    DosageView
    Instill 1 drop in the affected eye(s) 4 times a day or as needed.
    Side effectsView
    Burning, Eye Irritation or Pruritus, Visual disturbance, Ocular discharge were reported with this eye drop.
    ContraindicationsView
    This eye drop is contraindicated in patients with known hypersensitivity to any ingredient of the product.
    PrecautionsView
    Concomitant ocular medication should be administered 15 minutes prior to the instillation of this eye drop.
    InteractionsView
    Not known.
    Pregnancy & lactationView
    Safe use during pregnancy and lactation has not been established.
    Pediatric usageView
    Pediatric use: This eye drop should not be used in infants and small children under 3 years.

    Geriatric use: No overall differences in safety or effectiveness have been observed between elderly and other adult patients.
    StorageView
    The drug is to be used within 30 days after the first opening. Store at temperature not exceeding 30°C in a dry place. Protect from light. The bottle is to be closed strongly immediately after use. Keep away from the reach of children.

    Lacrigel G

    Carboxymethylcellulose Sodium + Glycerin
    Ophthalmic Solution 0.5%+0.9% Allopathic Drugs for Dry eyes

    Indications

    Irritation and discomfort of the eye

    Indication detailsView
    This Sterile Eye Drops is indicated for the temporary relief of burning, irritation, and discomfort due to dryness of the eye or exposure to wind or sun.
    Therapeutic classView
    Drugs for Dry eyes
    PharmacologyView
    The combination of Carboxymethylcellulose Sodium and Glycerin relieves the symptoms of dry eye in two ways. Firstly it provides lubricating and hydrating protective shield on the ocular surface of the eye and then it works below the tear film to provide protection to the cornea.
    DosageView
    Instill 1 drop in the affected eyes as needed. It can be used in children.
    Side effectsView
    Vision may be temporarily blurred when this product is first used. Also, minor burning/ stinging/ irritation may temporarily occur.
    ContraindicationsView
    It is contraindicated in patients with known hypersensitivity to any ingredient of this formulation.
    PrecautionsView
    Consult doctor if irritation, eye pain or visual changes worsen or persist beyond 72 hours.
    Pregnancy & lactationView
    Use in pregnancy: There are no adequate and well-controlled studies in pregnant women. Carboxymethylcellulose Sodium and Glycerin should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.

    Use in lactation: Carboxymethylcellulose Sodium or Glycerin has not been measured in human milk. Caution should be exercised when the combination of Carboxymethylcellulose Sodium and Glycerin is administered to a nursing mother.
    StorageView
    Store below 30°C. Protect from light. Do not use longer than 1 month after 1st opening. Do not freeze.

    Lacrima

    Dextran + Hypromellose
    Ophthalmic Solution 0.1%+0.3% Allopathic Drugs for Dry eyes

    Indications

    Dry eye

    Indication detailsView
    As a lubricant and artificial tear in dry eye and other ocular irritation syndromes associated with deficient tear or mucous secretion. This combination also prevents cornea to damage in patients with keratoconjunctivitis and for ocular lubrication. It is also used for the temporary relief of burning and irritation due to dryness of the eye and for use as the protectant against further irritation.
    Therapeutic classView
    Drugs for Dry eyes
    PharmacologyView
    Dextran & Hypromellose combination Eye drops acts like natural tears, which provides smoothing relief to dry, itchy, burning and irritated eyes. It helps eyes to stay moist
    healthy and protects against further irritation. This unique combination of ingredients works together to retain moisture on the eye and slow evaporation of the tear film.

    Hypromellose promotes corneal wetting by stabilizing and thickening the precorneal tear film and prolonging the tear film breakup time, which is usually shortened in dry eye conditions. Also acts to lubricate and protect the eye. Dextran is a complex branched glucan composed of chains of varying lengths. It is used medicinally as an antithrombotic, to reduce blood viscosity, and as a volume expander in hypovolaemia.
    DosageView
    Adults and children: One or two drops three times daily or as directed by the physician.
    Side effectsView
    There are no known side effects with the use of it, however, if the patient experiences any reaction in eye or other part of the body after using this medication then consult with doctor
    ContraindicationsView
    This product contains Benzalkonium Chloride and should not be used when soft contact lenses are being worn.
    PrecautionsView
    If irritation persists or if the condition does not improve, patient should seek further advice from doctor.
    Pregnancy & lactationView
    There is insufficient evidence as to the safety in pregnancy and lactation. Therefore, this product should only be used in pregnancy and lactation if it is considered essential by the physician.
    StorageView
    Store below 25°C and do not freeze. Do not use after 30 days of first opening. Keep the container closed tightly after each opening. Keep out of the reach of children.

    Lacrin

    Carboxymethylcellulose Sodium + Glycerin
    Ophthalmic Solution 0.5%+0.9% Allopathic Drugs for Dry eyes

    Indications

    Irritation and discomfort of the eye

    Indication detailsView
    This Sterile Eye Drops is indicated for the temporary relief of burning, irritation, and discomfort due to dryness of the eye or exposure to wind or sun.
    Therapeutic classView
    Drugs for Dry eyes
    PharmacologyView
    The combination of Carboxymethylcellulose Sodium and Glycerin relieves the symptoms of dry eye in two ways. Firstly it provides lubricating and hydrating protective shield on the ocular surface of the eye and then it works below the tear film to provide protection to the cornea.
    DosageView
    Instill 1 drop in the affected eyes as needed. It can be used in children.
    Side effectsView
    Vision may be temporarily blurred when this product is first used. Also, minor burning/ stinging/ irritation may temporarily occur.
    ContraindicationsView
    It is contraindicated in patients with known hypersensitivity to any ingredient of this formulation.
    PrecautionsView
    Consult doctor if irritation, eye pain or visual changes worsen or persist beyond 72 hours.
    Pregnancy & lactationView
    Use in pregnancy: There are no adequate and well-controlled studies in pregnant women. Carboxymethylcellulose Sodium and Glycerin should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.

    Use in lactation: Carboxymethylcellulose Sodium or Glycerin has not been measured in human milk. Caution should be exercised when the combination of Carboxymethylcellulose Sodium and Glycerin is administered to a nursing mother.
    StorageView
    Store below 30°C. Protect from light. Do not use longer than 1 month after 1st opening. Do not freeze.

    Lacrison

    Loteprednol Etabonate
    Ophthalmic Suspension 0.50% Allopathic Ophthalmic Steroid preparations
    Indication detailsView
    Loteprednol ophthalmic gel: This is indicated for the treatment of post-operative inflammation and pain following ocular surgery. It is also effective in steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the eyeball such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis & cyclitis.

    Loteprednol ophthalmic suspension: This is indicated in steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the eyeball such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis & cyclitis. It is also effective in post-operative inflammation.
    Therapeutic classView
    Ophthalmic Steroid preparations
    PharmacologyView
    Loteprednol is a corticosteroid which is thought to act by the induction of phospholipase A2 inhibitory proteins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid.
    DosageView
    Loteprednol ophthalmic gel: Instill one to two drops of Ophthalmic Gel into the conjunctival sac of the affected eye four times daily beginning the day after surgery and continuing throughout the first 2 weeks of the postoperative period.

    Loteprednol ophthalmic suspension:
    • For steroid-responsive ocular inflammation: Instill 1 drop of Ophthalmic Suspension into the conjunctival sac of the eye(s) four times a day.
    • For inflammation after surgery: Instill 1 drop of Ophthalmic Suspension into the conjunctival sac of the operated eye(s) four times a day beginning 24 hours after surgery and continuing throughout the first two weeks after surgery.
    Use in children: Safety and effectiveness in pediatric patients have not been established.
    Side effectsView
    Glaucoma with optic nerve damage, visual acuity and field defects; cataract formation; secondary ocular infection following suppression of host response; and perforation of the globe may occur.
    ContraindicationsView
    It is contraindicated in most viral diseases of the cornea and conjunctiva. It is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.
    PrecautionsView
    For ophthalmic use only. If this product is used for 10 days or longer, intraocular pressure should be monitored. Fungal infections of the cornea are particularly prone to develop coincidentally with long-term use of steroid topically. Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and visual field, and in posterior subcapsular cataract formation. Use of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution.
    Pregnancy & lactationView
    No clinical data available for use in pregnancy. It is not known whether Loteprednol Etabonate passes into breast milk.
    StorageView
    Protect from light. Store in cool & dry place. Keep out of the reach of children.

    Lacrison T

    Loteprednol Etabonate + Tobramycin
    Ophthalmic Suspension 0.5%+0.3% Allopathic Ophthalmic steroid - antibiotic combined preparations

    Indications

    Ocular inflammation

    Indication detailsView
    This is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis. It is also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. This is also indicated for the treatment of post-operative inflammation following ocular surgery.
    Therapeutic classView
    Ophthalmic steroid - antibiotic combined preparations
    PharmacologyView
    Loteprednol is a corticosteroid which is thought to act by the induction of phospholipase A2 inhibitory proteins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid.

    Tobramycin is a member of aminoglycoside which shows bactericidal activity by inhibiting protein synthesis of bacteria.
    DosageView
    Shake well before use. Apply one drop into the conjunctival sac of the affected eye(s) every four to six hours. During the initial 24 to 48 hours, the dosing may be increased, to every one to two hours.
    Side effectsView
    Increased intraocular pressure, burning and stinging upon instillation, vision disorders, discharge, itching, lacrimation disorder, photophobia, corneal deposits, ocular discomfort, eyelid disorder, and other unspecified eye disorders may occur. The incidence of non-ocular adverse events (headache) also reported.
    ContraindicationsView
    Contraindicated in most viral diseases of the cornea and conjunctiva. Also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.
    PrecautionsView
    • For ophthalmic use only.
    • If this product is used for 10 days or longer, intraocular pressure should be monitored.
    • Fungal infections of the cornea are particularly prone to develop coincidentally with long-term use of steroid topically.
    • Prolonged use may result in overgrowth of nonsusceptible organisms including fungi. If superinfection occurs, appropriate therapy should be initiated.
    • Cross-sensitivity to other aminoglycoside antibiotics may occur.
    InteractionsView
    Since Loteprednol Etabonate is not detected in plasma following the topical administration, it is not expected to affect the pharmacokinetics of systemically administered medicinal products.
    Pregnancy & lactationView
    Use in pregnancy: There are no adequate and well-controlled studies in pregnant women. Loteprednol Etabonate & Tobramycin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

    Use in lactation: Caution should be exercised when Loteprednol Etabonate & Tobramycin is administered to a nursing mother.
    Pediatric usageView
    Use in children: Safety and effectiveness in pediatric patients have not been established.
    StorageView
    Store at room temperature & protect from light. Do not touch dropper tip to any surface. It is desirable that the contents should not be used four weeks after first opening of the bottle. Protect from freezing.

    Lactameal

    Aluminium Hydroxide + Magnesium Hydroxide
    Oral Suspension (175 mg+225 mg)/5 ml Allopathic Antacids

    Indications

    Upper Gl bloating

    Indication detailsView
    Aluminium Hydroxide and Magnesium Hydroxide is indicated for Hyperacidity, peptic ulcer, gastritis, heartburn, sour stomach & dyspepsia.
    Therapeutic classView
    Antacids
    PharmacologyView
    This drug is well-balanced combination of essential non-systemic antacids which excel in efficacy and palatability. These are dependable antacid preparations without acid rebound, constipating or cathertic effects. Both the preparations provide symptomatic relief of hyperacidity associated with heartburn, acid ingestion or sour stomach.

    Aluminium hydroxide gel, a slow acting antacid and an adsorbent with prolonged effect, has high neutralizing power. Magnesium Hydroxide possesses a slow but sustained acid neutralizing property. Antacids of both tablet and suspension possess adsorbent property. They form a protecting coating over the ulcer surface facilitating its healing; thus protecting the sensitive mucosa of stomach and duodenum from further irritation.
    DosageView
    Tablet: Two tablets 1-3 hours after meal and at bed time or as directed by the physician.

    Suspension: 2 tea spoonful 1-3 hours after meal and at bed time or as directed by the physician.
    Side effectsView
    Long term use of any antacid results in alkaluria, which may predispose to nephrolithiasis by forming precipitation of calcium phosphate.
    ContraindicationsView
    This is contraindicated in hypophosphataemia. It is also contraindicated in alkalosis and hypermagnesaemia where abdominal distention may be due to partial or complete intestinal obstruction.
    PrecautionsView
    Antacids reduce the absorption of tetracycline when given concomitantly. These should not be used concomitantly
    InteractionsView
    This drug inhibits the absorption of following drugs: Azithromycin, cefpodoxime, ciprofloxacin, isoniazid, rifampicin, norfloxacin, ofloxacin, pivampicillin, tetracyclines, Gabapentin and phenytoin, Itraconazole, ketoconazole, Chloroquine, hydroxychloroquine and Phenothiazines.
    Pregnancy & lactationView
    It is advised to avoid antacid preparations in the first trimester of pregnancy.
    StorageView
    Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

    Lactameal

    Aluminium Hydroxide + Magnesium Hydroxide
    Chewable Tablet 250 mg+400 mg Allopathic Antacids

    Indications

    Upper Gl bloating

    Indication detailsView
    Aluminium Hydroxide and Magnesium Hydroxide is indicated for Hyperacidity, peptic ulcer, gastritis, heartburn, sour stomach & dyspepsia.
    Therapeutic classView
    Antacids
    PharmacologyView
    This drug is well-balanced combination of essential non-systemic antacids which excel in efficacy and palatability. These are dependable antacid preparations without acid rebound, constipating or cathertic effects. Both the preparations provide symptomatic relief of hyperacidity associated with heartburn, acid ingestion or sour stomach.

    Aluminium hydroxide gel, a slow acting antacid and an adsorbent with prolonged effect, has high neutralizing power. Magnesium Hydroxide possesses a slow but sustained acid neutralizing property. Antacids of both tablet and suspension possess adsorbent property. They form a protecting coating over the ulcer surface facilitating its healing; thus protecting the sensitive mucosa of stomach and duodenum from further irritation.
    DosageView
    Tablet: Two tablets 1-3 hours after meal and at bed time or as directed by the physician.

    Suspension: 2 tea spoonful 1-3 hours after meal and at bed time or as directed by the physician.
    Side effectsView
    Long term use of any antacid results in alkaluria, which may predispose to nephrolithiasis by forming precipitation of calcium phosphate.
    ContraindicationsView
    This is contraindicated in hypophosphataemia. It is also contraindicated in alkalosis and hypermagnesaemia where abdominal distention may be due to partial or complete intestinal obstruction.
    PrecautionsView
    Antacids reduce the absorption of tetracycline when given concomitantly. These should not be used concomitantly
    InteractionsView
    This drug inhibits the absorption of following drugs: Azithromycin, cefpodoxime, ciprofloxacin, isoniazid, rifampicin, norfloxacin, ofloxacin, pivampicillin, tetracyclines, Gabapentin and phenytoin, Itraconazole, ketoconazole, Chloroquine, hydroxychloroquine and Phenothiazines.
    Pregnancy & lactationView
    It is advised to avoid antacid preparations in the first trimester of pregnancy.
    StorageView
    Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

    Lacticare

    Lactic acid + Sodium PCA
    Lotion 5%+2.5% Allopathic Emollients & combined preparations

    Indications

    Skin care

    Indication detailsView
    This medication is used as a moisturizer to treat or prevent dry, rough, scaly, itchy skin and minor skin irritations (e.g., diaper rash, skin burns from radiation therapy). Emollients are substances that soften and moisturize the skin and decrease itching and flaking. Some products (e.g., zinc oxide, white petrolatum) are used mostly to protect the skin against irritation (e.g., from wetness).
    Therapeutic classView
    Emollients & combined preparations
    PharmacologyView
    Lactic acid: It is commonly used for lubricating and moisturising skin, thus relieving dryness and itch.

    Sodium PCA: It is a keratolytic agent. It encourages exfoliation of the skin and opening up of the plugged follicles, which helps re-establish the normal skin- cell replacement cycle. For milder acne, salicylic acid helps unclog pores to resolve and prevent lesions.
    DosageView
    Use as required on affected areas.
    Side effectsView
    Most emollients can be used safely and effectively with no side effects. However, burning, stinging, redness, or irritation may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.
    ContraindicationsView
    Hypersensitivity
    PrecautionsView
    Before using this product, tell your doctor or pharmacist if you are allergic to any of the ingredients in the product; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.
    Pregnancy & lactationView
    Pregnancy category is not classified. FDA has not yet classified the drug into a specified pregnancy category.

    Lacticon

    Lactitol Monohydrate
    Oral Powder 10 gm/sachet Allopathic Osmotic purgatives

    Indications

    Hepatic encephalopathy

    Indication detailsView
    Lactitol Monohydrate is indicated in chronic idiopathic constipation (CIC), acute and chronic portal systemic encephalopathy.
    Therapeutic classView
    Osmotic purgatives
    PharmacologyView
    Lactitol Monohydrate is a disaccharide derivatives consisting of galactose and sorbitol, which is only minimally absorbed and is not hydrolysed by the disaccharidases of the GIT and thus reaches the colon unchanged. In the colon it is broken down to short chain low molecular weight organic acids by the intestinal flora, resulting in an increase in osmotic pressure in the colon, thereby causing an increase in the stool water content and stool volume, which explains the laxative effect. Lactitol Monohydrate produces its effect in the lumen of the colon, where it is virtually 100% bioavailable. It is absorbed only in minimal amounts. Up to 2% can be found unchanged in the urine.
    DosageView
    Lactitol can be mixed with hot or cold beverages, puddings etc. Dosage will require adjustment to obtaine one daily bowel movement in constipated patients and two daily bowel movements in patients with portal systemic encephalopathy.

    In constipation: In adult: The initial daily dosage should be 20 g taken in a single dose with the morning or evening meal. After a few days, a daily dose of 10 g may be sufficient.

    Children: The mean dosage is 0.25 g/kg body weight daily.
    • 1 to 6 years: 2.5 to 5 gm
    • 6 to 12 years: 5 to 10 gm
    • 12 to 16 years: 10 to 20 gm
    The effect of lactitol has been found mostly to occur within a few hours after intake. But in some cases the first laxative response may be delayed until the second or third day of administration. Therefore patients should be advised to maintain an adequate daily fluid intake.

    In portal systemic encephalopathy: The dose should be adjusted according to the severity of the patient’s disease and their individual response. The initial recommended dose is 0.5 to 0.7 gm/kg body weight daily, divided into three daily doses with meals.
    Side effectsView
    At the start of the treatment with lactitol may produce abdominal discomforts such as flatulence, pain, cramps or sensation of fullness. Such effects tend to diminish or disappear after a few days of regular intake of Lactitol. Occasionally, nausea or anal pruritus has been reported in some cases.
    ContraindicationsView
    Patients with known hypersensitivity to any of the ingredients of this preparation.
    PrecautionsView
    • Elderly or debilitated patients receiving long-term treatment with lactitol should have their serum electrolytes monitored regularly.
    • As for all laxatives, pre-existing fluid or electrolyte imbalance should be corrected before starting treatment with lactitol.
    • Following treatment of Lactitol, hydrogen may accumulate in the bowel. Patients who need to undergo electrocauterisation procedure should therefore have a thorough bowel cleansing with a non-fermentable solution.
    • Lactitol is not recommended in case s of ileostomy or colostomy.
    • Prolonged use of laxatives without interruption should be avoided.
    InteractionsView
    Antacids and neomycin should not be given simultaneously with Lactitol to cirrhotic patients with portal systemic encephalopathy. Lactitol may increase potassium loss caused by other drugs e.g. thiazide diuretics, corticosteroids, carbenoxolone, amphotericin B and it may enhance the risk of toxic effects of glycosides in patients receiving concomitant therapy.
    Pregnancy & lactationView
    Lactitol is minimally absorbed systemically following oral administration, and it is unknown whether maternal use will result in fetal exposure to the drug. There are no data on the presence of lactitol in human or animal milk, the effects on the breastfed infant, or the effects on milk production.
    StorageView
    Store in a cool, dry place and away from light. Keep out of reach of children.